Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All of below Pediatric patients undergoing surgery under general anesthesia with requirement of early reversal of neuromuscular blockade Aged between 2 and 17 American Society of Anesthesiologists Physical Status Classification 1 and 2~Exclusion Criteria:~* Any of below One or more legal guardian declines to enroll in the study History of hypersensitivity to any anesthetic agents including rocuronium Presence of underlying cardiovascular or genitourinary disease Under usage of neuromuscular blocking agents before surgery Under usage of drugs influencing the effect of neuromuscular blocking agents History of malignant hyperthermia Anticipation of massive hemorrhage during surgery

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Sugammadex 2mg (Type: EXPERIMENTAL): Administer 2mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
- Sugammadex 4mg (Type: EXPERIMENTAL): Administer 4mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
- Sugammadex 8mg (Type: EXPERIMENTAL): Administer 8mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
- Conventional reversal (Type: ACTIVE_COMPARATOR): Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) on reappearance of T2 by Train-of-Four stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).